CBGE & DDD Roadshow in Lund | From Decoding Biology to Drug Discovery

Organizer

SciLifeLab Lund
lund@scilifelab.se
View Organizer Website

Venue

Belfragesalen
BMC D15, Klinikgatan 32
Lund, Sweden

CBGE & DDD Roadshow in Lund | From Decoding Biology to Drug Discovery

March 5, 2025 @ 11:00 15:00 CET

SciLifeLab Lund is pleased to welcome SciLifeLab Chemical Biology & Genome Engineering Platform (CBGE) and Drug Discovery and Development Platform (DDD) and host their Roadshow in Lund.

During the seminar “Small Molecules, CRISPR & Chemical Proteomics: From Decoding Biology to Drug Discovery”, we will have a look into both platforms and an user will showcase a project carried out in collaboration with them. The Seminar will be followed by a light lunch and individual consultation meetings.

The SciLifeLab Chemical Biology & Genome Engineering Platform

  •             Anna-Lena Gustavsson, Platform director, KI
  •             Fredrik Ek, Chemical Biology Consortium Sweden, LU
  •             Bernhard Schmierer, CRISPR Functional Genomics, KI
  •             Massimiliano Gaetani  Chemical Proteomics, KI

The SciLifeLab Drug Discovery and Development Platform

  •             Per Arvidsson, Platform director, KI

User presentation

  • Functional chemical reprogramming of cancer cells to induce antitumor immunity. Fábio Fiúza Rosa. Co-founder and Head of Research, Asgard Therapeutics AB, prev.  Filipe Pereira research group LU.
BMC D15, Klinikgatan 32
Lund, Sweden
+ Google Map

Last updated: 2025-02-13

Content Responsible: Anabella Aguilera(anabella.aguilera@slu.se)

Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.
Help Us Improve!
We want to better match our services with your needs—take our short survey and help shape SciLifeLab’s digital future. You can also join our user panel for occasional feedback opportunities and early access to new tools.